165 related articles for article (PubMed ID: 16312147)
1. Practical enantioselective process for a chiral phosphodiesterase-4 inhibitor.
Chen CY
Curr Opin Drug Discov Devel; 2005 Nov; 8(6):709-22. PubMed ID: 16312147
[TBL] [Abstract][Full Text] [Related]
2. Practical asymmetric synthesis of a potent PDE4 inhibitor via stereoselective enolate alkylation of a chiral aryl-heteroaryl secondary tosylate.
O'Shea PD; Chen CY; Chen W; Dagneau P; Frey LF; Grabowski EJ; Marcantonio KM; Reamer RA; Tan L; Tillyer RD; Roy A; Wang X; Zhao D
J Org Chem; 2005 Apr; 70(8):3021-30. PubMed ID: 15822960
[TBL] [Abstract][Full Text] [Related]
3. Preparation of pyrrolidine-based PDE4 inhibitors via enantioselective conjugate addition of alpha-substituted malonates to aromatic nitroalkenes.
Nichols PJ; Demattei JA; Barnett BR; Lefur NA; Chuang TH; Piscopio AD; Koch K
Org Lett; 2006 Mar; 8(7):1495-8. PubMed ID: 16562925
[TBL] [Abstract][Full Text] [Related]
4. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
[TBL] [Abstract][Full Text] [Related]
5. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
[TBL] [Abstract][Full Text] [Related]
6. Novel approaches to using PDE4 inhibitors for antihypertensive therapy.
Wang D; Wang T
Curr Opin Investig Drugs; 2005 Mar; 6(3):283-8. PubMed ID: 15816505
[TBL] [Abstract][Full Text] [Related]
7. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Smith VB; Spina D
Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
[TBL] [Abstract][Full Text] [Related]
8. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
10. 2,1,3-Benzothiadiazine derivatives: synthesis and screening versus PDE4 enzyme.
Tait A; Luppi A; Avallone R; Baraldi M
Farmaco; 2005 Aug; 60(8):653-63. PubMed ID: 15963514
[TBL] [Abstract][Full Text] [Related]
11. Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.
Huai Q; Sun Y; Wang H; Macdonald D; Aspiotis R; Robinson H; Huang Z; Ke H
J Med Chem; 2006 Mar; 49(6):1867-73. PubMed ID: 16539372
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and profile of SCH351591, a novel PDE4 inhibitor.
Billah M; Cooper N; Cuss F; Davenport RJ; Dyke HJ; Egan R; Ganguly A; Gowers L; Hannah DR; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Naylor R; Oxford J; Peake JC; Piwinski JJ; Runcie KA; Sabin V; Sharpe A; Shih NY; Warneck JB
Bioorg Med Chem Lett; 2002 Jun; 12(12):1621-3. PubMed ID: 12039576
[TBL] [Abstract][Full Text] [Related]
13. First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives.
Provins L; Christophe B; Danhaive P; Dulieu J; Durieu V; Gillard M; Lebon F; Lengelé S; Quéré L; van Keulen B
Bioorg Med Chem Lett; 2006 Apr; 16(7):1834-9. PubMed ID: 16439121
[TBL] [Abstract][Full Text] [Related]
14. Enaminones 9. Further studies on the anticonvulsant activity and potential type IV phosphodiesterase inhibitory activity of substituted vinylic benzamides.
Anderson AJ; Nicholson JM; Bakare O; Butcher RJ; Wilson TL; Scott KR
Bioorg Med Chem; 2006 Feb; 14(4):997-1006. PubMed ID: 16219468
[TBL] [Abstract][Full Text] [Related]
15. Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.
Van der Mey M; Boss H; Couwenberg D; Hatzelmann A; Sterk GJ; Goubitz K; Schenk H; Timmerman H
J Med Chem; 2002 Jun; 45(12):2526-33. PubMed ID: 12036361
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of a naphthyridone p38 MAP kinase inhibitor.
Chung JY; Cvetovich RJ; McLaughlin M; Amato J; Tsay FR; Jensen M; Weissman S; Zewge D
J Org Chem; 2006 Oct; 71(22):8602-9. PubMed ID: 17064039
[TBL] [Abstract][Full Text] [Related]
17. New orally active PDE4 inhibitors with therapeutic potential.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective synthesis of novel pyrazole derivatives using tert-butansulfonamide as a chiral auxiliary.
Park CM; Jeon DJ
Org Biomol Chem; 2012 Apr; 10(13):2613-20. PubMed ID: 22371117
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.
Tait A; Luppi A; Hatzelmann A; Fossa P; Mosti L
Bioorg Med Chem; 2005 Feb; 13(4):1393-402. PubMed ID: 15670947
[TBL] [Abstract][Full Text] [Related]
20. Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560.
Bateman KP; Trimble L; Chauret N; Silva J; Day S; Macdonald D; Dube D; Gallant M; Mastracchio A; Perrier H; Girard Y; Nicoll-Griffith D
J Mass Spectrom; 2006 Jun; 41(6):771-80. PubMed ID: 16705670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
